AMGN vs BXC · P/E 24, rev $10.05B vs rev $1.55B
Amgen Inc (AMGN) versus BlueLinx Holdings Inc (BXC) — a side-by-side from cached financials, not a winner call.
Amgen Inc (AMGN) is a drug manufacturers - general company listed on US.
BlueLinx Holdings Inc (BXC) is a industrial distribution company listed on NYSE.
Latest reported AMGN revenue for 2026-06-30 was $10.05B. Net income was $2.38B. Revenue was up 16.7% from 2026-03-31 to 2026-06-30. AMGN currently screens at market cap $188.67B and trailing P/E 24.3.
Latest reported BXC revenue for 2026-07-04 was $1.55B. Net income was $4.9M. BXC currently screens at market cap $423.4M.
AMGN currently screens at market cap $188.67B and trailing P/E 24.3. BXC currently screens at market cap $423.4M.
Not investment advice. Open the AMGN and BXC stock pages for the full models.
Not investment advice.